Loading stock data…
DERM
$5.00-0.07 (-1.38%)
Market ClosedLast close May 11
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Journey Medical Corporation in the Healthcare sector is trading at $5.00. The stock is currently near its 52-week low of $4.31, remaining 31.5% below its 200-day moving average. Technical signals show neutral RSI of 53 and bullish MACD crossover, explaining why DERM maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.00
Potential Upside
5%
Whystock Fair Value$5.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$13.50+170.0%
Range$12.00 – $16.00
Fundamentals
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$167.61M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.89%
Volume
Today's trading volume
328,152
Recent News
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of +38.89% and +0.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +184.36% and +15.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know
Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks
Journey Medical's fair value target has been adjusted to $13.25 from $13.50, putting a fresh spotlight on how analysts are framing the story around the stock. Some bullish voices see the updated target as a sign that current pricing does not fully capture the company’s recent execution, while more cautious views point out that the target still leans on consistent revenue momentum and margin discipline. As you read on, you will see how these differing opinions shape the evolving analyst...